59216-77-2

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 5-HYDROXY-2-NITROBENZOATE is used as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients for its ability to contribute to the development of new medications.
Used in Chemical Industry:
METHYL 5-HYDROXY-2-NITROBENZOATE is used as a component in the manufacturing of dyes and pigments, playing a role in the production of colorants for different applications.
Used in Organic Synthesis:
METHYL 5-HYDROXY-2-NITROBENZOATE is used as a reagent in organic synthesis processes, facilitating the creation of a range of organic compounds for various purposes.

Upstream product

• 67-56-1 methanol 
• 610-37-7 5-hydroxy-2-nitrobenzoic acid 
• 99-06-9 3-Carboxyphenol 
• 42454-06-8 2-nitro-5-hydroxybenzaldehyde 

Downstream Products

• 499973-04-5 methyl 2-nitro-5-(prop-2-ynyloxy)benzoate 
• 485824-59-7 methyl 2-nitro-5-(thien-2-ylmethoxy)benzoate 
• 116027-17-9 2-amino-5-benzyloxybenzoic acid methyl ester 
• 1007374-13-1 C₁₈H₂₁NO₃ 

Relevant academic research and scientific papers

Preparation technology of 6-hydroxy-bentazone

The invention discloses a preparation technology of 6-hydroxy-3-isopropyl-1H-benzo[c][1,2,6]thiadiazine-4(3H)-keto-2,2-dioxide. The preparation technology includes subjecting 5-chloro-2-nitrobenzoic acid serving as a raw material to hydrolysis reaction an

HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF

The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.

Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists

Herein, we report studies leading to the discovery of the neoseptins and a comprehensive examination of the structure-activity relationships (SARs) of this new class of small-molecule mouse Toll-like receptor 4 (mTLR4) agonists. The compounds in this class, which emerged from screening an α-helix mimetic library, stimulate the immune response, act by a well-defined mechanism (mouse TLR4 agonist), are easy to produce and structurally manipulate, exhibit exquisite SARs, are nontoxic, and elicit improved and qualitatively different responses compared to lipopolysaccharide, even though they share the same receptor.

SUBSTITUTED TRIAZOLOBENZODIAZEPINES

This invention relates to novel substituted triazolobenzodiazepines of the Formula (I), wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this

NEOSEPTINS: SMALL MOLECULE ADJUVANTS

A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay

Optimization efforts on the anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors 1 and 2 resulted in the identification of multiple structural elements that contributed to improved cell culture potency. The additive effect of these elements resulted in compound 46, an inhibitor with enzymatic (IC50) and cell culture (EC50) potencies of less than 100 nanomolar.

QUINAZOLINONE DERIVATIVES AS VIRAL POLYMERASE INHIBITORS

Compounds of formula I: (I) wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM

The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the HIV gp41 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN36 (SEQ ID NO:1); a second helical polypeptide consisting essentially of the sequence of C34 (SEQ ID NO: 2) wherein said IQN36 is labeled with a light emitting fluorophore and said C34 is labeled with an ultra-violet excitable fluorophore.

VIRAL POLYMERASE INHIBITORS

The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical

VIRAL POLYMERASE INHIBITORS

Compounds of formula I: wherein X, R2, R3, R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.